ADVERTISEMENT
  • Home
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms of Service
  • Editorial Guidelines
Tuesday, July 5, 2022
Life Care News
  • Home
  • Business
    • BusinessWire
    • GlobeNewswire
    • Banking
  • News

    Professor Sir Ralf Speth, Chairman of TVS Motor Company, Admitted as a Fellow of The Royal Society

    IGP Launches Designer Rakhi Collection, With Over 3000+ Designs

    SBI Card Partners with Aditya Birla Finance to Launch ‘Aditya Birla SBI Card’

    TVS Motor Company Sales Grows by 22 percent in June 2022

    CloudThat is Recognized as a 2022 Partner of the Year Finalist-Learning Award for the Second Time in 3 years

    Nanda & Nanda Advocates, Ashish Bhutani, Sumit Arora, Anshul Gupta and Ankur Arora Conferred with Times 40 Under 40 Awards 2022

    Global Performance Marketing Giant Adsparkx Turns to Bollywood to Foster Pride Month Awareness

    Fidel Softech IPO Receives Good Investor Response

    Biesse India Along with IIID Bengaluru Organises a Workshop on Design Concepts

    APL Apollo Launches Colour Coated Coils and Sheets First Time in India

    Trending Tags

    • Donald Trump
    • Future of News
    • Climate Change
    • Market Stories
    • Election Results
    • Flat Earth
    • Startups
    • Feature News
    • Energy
    • Real Estate
    • Environment
    • Uncategorized
  • Tech

    NORD Duodrive Now With Powers Of Up To 3 Kw Patented Geared Motor For Ultimate Energy Efficiency

    MTAR Technologies Limited Receives Orders of USD 22.12 Million in Clean Energy

    Rohde & Schwarz Offers New Ultra-Wideband Test Solution Validated for FiRa Consortium PHY Conformance

    Power League Gaming Names Langoor as New Digital Transformation Agency Partner

    Rohde & Schwarz extends the R&S ZNB vector network analyzer family maximum frequency to 43.5 GHz

    Rohde & Schwarz enhances R&S RTP high-performance oscilloscope

    Automating Battery Production for eMobility Applications

    ecom instruments at the Hannover Messe 2022: Smart Devices for the Digitalization of Hazardous Areas

    The Fischer family has created the technology group Conextivity to extend its expertise and innovation

    RAMINFO growth momentum continues in Q4 FY22 with 366% YoY rise in Net Profit

    Trending Tags

    • Flat Earth
    • Sillicon Valley
    • Mr. Robot
    • MotoGP 2017
    • Golden Globes
    • Future of News
  • Entertainment

    AndTV Actors and Their Favourite Corners at Home!

    GameOn Announces US$560,000 Loan On Path to Profitability

    Public vote winner of €2,000 selected in Be Open’s DESIGN TO NURTURE THE PLANET, international competition to support the SDGs

    AndTV Par Hogi Bhavnaao Ki Pariksha!

    Applause Entertainment Extends its Footprint in the South; Sets up an Office in Chennai

    ELLE FANNING – THE AMBASSADOR OF FAME, PACO RABANNE’S NEW FEMININE FRAGRANCE

    CGTN: Integration into national development brings new impetus to Hong Kong

    Fabrique 1840 Award 2022 Winners Announced

    Xinhua Silk Road: 2022 World Canal Cities Forum held in Yangzhou, east China

    CGTN: Hong Kong on highway to become global tech and innovation hub 25 years on

    • Lifestyle

      ChildCare Education Institute Offers No-Cost Online Course

      Author Whynde Kuehn Previews the Upcoming Release of

      First Time in World History Hindu Religion and Buddha Religion come Together and Start a Dialogue in Cambodia

      International and Domestic manufacturers and exporters from 15 countries to showcase latest in apparel, textile and fashion industry innovations at ASW 2022

      Asian Paints has Launched their 2022 Collection in Home Decor

      California Pistachio Brings to Life

      It’s Rally Time for Houston’s Teachers

      Pearl Green Clubs and Resorts Limited to Raise Rs. 1171.80/- Lakhs through SME IPO, Issue Opens on June 27, 2022

      One in Two Women Cite Yoga to be their Panacea to Beat the Blues

      Chargebee Earns 2022 US Great Place to Work Certification™

      Trending Tags

      • Golden Globes
      • Mr. Robot
      • MotoGP 2017
      • Climate Change
      • Flat Earth
    • Fashion
    • Travel
  • Health
    • Food
  • Education
    • Books
  • Technology
  • Automobile
  • Sports
    • Olympic
No Result
View All Result
Life Care News
  • Home
  • Business
    • BusinessWire
    • GlobeNewswire
    • Banking
  • News

    Professor Sir Ralf Speth, Chairman of TVS Motor Company, Admitted as a Fellow of The Royal Society

    IGP Launches Designer Rakhi Collection, With Over 3000+ Designs

    SBI Card Partners with Aditya Birla Finance to Launch ‘Aditya Birla SBI Card’

    TVS Motor Company Sales Grows by 22 percent in June 2022

    CloudThat is Recognized as a 2022 Partner of the Year Finalist-Learning Award for the Second Time in 3 years

    Nanda & Nanda Advocates, Ashish Bhutani, Sumit Arora, Anshul Gupta and Ankur Arora Conferred with Times 40 Under 40 Awards 2022

    Global Performance Marketing Giant Adsparkx Turns to Bollywood to Foster Pride Month Awareness

    Fidel Softech IPO Receives Good Investor Response

    Biesse India Along with IIID Bengaluru Organises a Workshop on Design Concepts

    APL Apollo Launches Colour Coated Coils and Sheets First Time in India

    Trending Tags

    • Donald Trump
    • Future of News
    • Climate Change
    • Market Stories
    • Election Results
    • Flat Earth
    • Startups
    • Feature News
    • Energy
    • Real Estate
    • Environment
    • Uncategorized
  • Tech

    NORD Duodrive Now With Powers Of Up To 3 Kw Patented Geared Motor For Ultimate Energy Efficiency

    MTAR Technologies Limited Receives Orders of USD 22.12 Million in Clean Energy

    Rohde & Schwarz Offers New Ultra-Wideband Test Solution Validated for FiRa Consortium PHY Conformance

    Power League Gaming Names Langoor as New Digital Transformation Agency Partner

    Rohde & Schwarz extends the R&S ZNB vector network analyzer family maximum frequency to 43.5 GHz

    Rohde & Schwarz enhances R&S RTP high-performance oscilloscope

    Automating Battery Production for eMobility Applications

    ecom instruments at the Hannover Messe 2022: Smart Devices for the Digitalization of Hazardous Areas

    The Fischer family has created the technology group Conextivity to extend its expertise and innovation

    RAMINFO growth momentum continues in Q4 FY22 with 366% YoY rise in Net Profit

    Trending Tags

    • Flat Earth
    • Sillicon Valley
    • Mr. Robot
    • MotoGP 2017
    • Golden Globes
    • Future of News
  • Entertainment

    AndTV Actors and Their Favourite Corners at Home!

    GameOn Announces US$560,000 Loan On Path to Profitability

    Public vote winner of €2,000 selected in Be Open’s DESIGN TO NURTURE THE PLANET, international competition to support the SDGs

    AndTV Par Hogi Bhavnaao Ki Pariksha!

    Applause Entertainment Extends its Footprint in the South; Sets up an Office in Chennai

    ELLE FANNING – THE AMBASSADOR OF FAME, PACO RABANNE’S NEW FEMININE FRAGRANCE

    CGTN: Integration into national development brings new impetus to Hong Kong

    Fabrique 1840 Award 2022 Winners Announced

    Xinhua Silk Road: 2022 World Canal Cities Forum held in Yangzhou, east China

    CGTN: Hong Kong on highway to become global tech and innovation hub 25 years on

    • Lifestyle

      ChildCare Education Institute Offers No-Cost Online Course

      Author Whynde Kuehn Previews the Upcoming Release of

      First Time in World History Hindu Religion and Buddha Religion come Together and Start a Dialogue in Cambodia

      International and Domestic manufacturers and exporters from 15 countries to showcase latest in apparel, textile and fashion industry innovations at ASW 2022

      Asian Paints has Launched their 2022 Collection in Home Decor

      California Pistachio Brings to Life

      It’s Rally Time for Houston’s Teachers

      Pearl Green Clubs and Resorts Limited to Raise Rs. 1171.80/- Lakhs through SME IPO, Issue Opens on June 27, 2022

      One in Two Women Cite Yoga to be their Panacea to Beat the Blues

      Chargebee Earns 2022 US Great Place to Work Certification™

      Trending Tags

      • Golden Globes
      • Mr. Robot
      • MotoGP 2017
      • Climate Change
      • Flat Earth
    • Fashion
    • Travel
  • Health
    • Food
  • Education
    • Books
  • Technology
  • Automobile
  • Sports
    • Olympic
No Result
View All Result
Life Care News
No Result
View All Result
ADVERTISEMENT
Home Uncategorized

HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760

by GlobeNewswire
10/01/2022
in Uncategorized
250 2
0
491
SHARES
1.4k
VIEWS
Share on FacebookShare on TwitterShare on WhatsApp
ADVERTISEMENT

— HMPL-760 is the eleventh innovative potential oncology drug candidate discovered in-house by HUTCHMED —

— HMPL-760 is HUTCHMED’s fifth candidate in clinical development for hematological malignancies, including amdizalisib and HMPL-523 that also target the B-cell receptor (“BCR”) signaling pathway, and tazemetostat and HMPL-306 —

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) has initiated a Phase I study in China of HMPL-760, a highly potent, selective, and reversible inhibitor with long target engagement against Bruton’s tyrosine kinase (“BTK”), including wild-type and C481S-mutated BTK. The first patient received their first dose on January 4, 2022.

The clinical study is a multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy profile of HMPL-760. The study is enrolling patients with previously treated chronic lymphocytic leukemia/​small lymphocytic lymphoma (CLL/SLL) or other types of Non-Hodgkin Lymphoma (“NHL”), including patients treated with a prior regimen containing a BTK inhibitor, whose disease carries either wild-type BTK or acquired resistance to first generation BTK inhibitors due to additional mutations to BTK.

Advertisement. Scroll to continue reading.

An initial dose escalation stage to determine the maximum tolerated dose (MTD) and/or the recommended Phase II dose (“RP2D”) is planned, to be followed by a dose expansion phase where patients will receive HMPL‑760 to further evaluate the safety, tolerability, and clinical activity at the RP2D. Approximately 100 patients are expected to be enrolled.

HMPL-760 is HUTCHMED’s fifth investigational drug candidate targeting hematological malignancies in clinical development. Amdizalisib (HMPL-689, targeting the delta isoform of phosphoinositide 3-kinase or PI3K delta) and HMPL-523 (targeting spleen tyrosine kinase or Syk) are also being studied in several Phase II trials against B-cell dominant malignancies. Phase II registration studies are underway in China for amdizalisib in patients with follicular lymphoma (FL), for which it has been granted Breakthrough Therapy Designation in China, and marginal zone lymphoma (MZL).

ADVERTISEMENT
ADVERTISEMENT

In addition to the three BCR inhibitors, for hematological malignancies HUTCHMED is also developing its in-house discovered drug candidate HMPL-306, a dual-inhibitor of mutant isocitrate dehydrogenase 1 and 2, and tazemetostat, a methyltransferase inhibitor of EZH2 (being developed in Greater China by HUTCHMED pursuant to a strategic collaboration with Epizyme).

About BTK and Non-Hodgkin Lymphoma

BTK is a key component of the B-cell receptor signaling pathway and is an important regulator of cell proliferation and cell survival in various lymphomas. The abnormal activation of B-cell receptor signaling is closely related to the development of B-cell type hematological cancers, which represent approximately 85% of all NHL cases.1 BTK is considered a validated target for drugs that aim to treat certain hematological cancers, however C481S mutation of BTK is a known resistance mechanism for first and second generation BTK inhibitors. In 2020, approximately 93,000 new cases of NHL are estimated to have been diagnosed in China.2

About HMPL-760

HMPL-760 is an investigational, highly selective, non-covalent, third-generation inhibitor of BTK, both wild-type and C481S mutant enzymes, with pre-clinical data suggesting high target specificity and higher potency versus first generation BTK inhibitors. BTK C481S mutation plays an important role in resistance to certain BTK inhibitors.3,4

HMPL-760 is HUTCHMED’s eleventh innovative potential oncology drug candidate to enter clinical development. HUTCHMED currently retains all rights to HMPL-760 worldwide.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:​HCM; HKEX: ​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,500 personnel across all its companies, at the center of which is a team of over 1,400 in oncology/​immunology. Since inception it has advanced 11 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

ADVERTISEMENT

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of HMPL-760, amdizalisib, HMPL-523, HMPL-306 and tazemetostat for patients, its expectations as to whether any studies on HMPL-760, amdizalisib, HMPL-523, HMPL-306 and tazemetostat would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of HMPL-760, amdizalisib, HMPL-523, HMPL-306 and tazemetostat, including as a combination therapy, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of HMPL-760, amdizalisib, HMPL-523, HMPL-306 and tazemetostat for a targeted indication; the sufficiency of funding; and the impact of the COVID-19 pandemic on general economic, regulatory and political conditions. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the U.S. Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

Advertisement. Scroll to continue reading.
Investor Enquiries  
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
   
Media Enquiries  
Americas – Brad Miles,
Solebury Trout
+1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Europe – Ben Atwell / Alex Shaw,
FTI Consulting
+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
HUTCHMED@fticonsulting.com
Asia – Zhou Yi,
Brunswick
+852 9783 6894 (Mobile)
HUTCHMED@brunswickgroup.com
   
Nominated Advisor  
Atholl Tweedie / Freddy Crossley,
Panmure Gordon (UK) Limited
+44 (20) 7886 2500

______________________________

Advertisement. Scroll to continue reading.

1 American Cancer Society (2019, January 29). Types of B-cell Lymphoma. https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/b-cell-lymphoma.html. Accessed January 5, 2022.
2 The Global Cancer Observatory, China fact sheet. https://gco.iarc.fr/today/data/factsheets/populations/160-china-fact-sheets.pdf. Accessed November 17, 2021.
3 Woyach JA, Ruppert AS, Guinn D, et al. BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol. 2017;35(13):1437-1443. doi:10.1200/JCO.2016.70.2282.
4 Woyach JA, Huang Y, Rogers K, et al. Resistance to Acalabrutinib in CLL is Mediated Primarily by BTK Mutations. Blood. 2019;134 (Supplement_1): 504. doi:10.1182/blood-2019-127674.

Tags: BTKHMPL760HUTCHMEDHUTCHMED (China) LimitedInhibitorInitiatesNasdaq:HCMPhaseStudy
Share196Tweet123Send
ADVERTISEMENT
Previous Post

Hybrid Software Group PLC: Financial reporting calendar

Next Post

908 Devices Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021

GlobeNewswire

GlobeNewswire

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Next Post

908 Devices Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021

Please login to join discussion
  • Trending
  • Comments
  • Latest

GreenCell Mobility Unveils ‘NueGo’ – First Pan-India Intercity Electric Mobility Coach Brand

22/04/2022

Sinch AB (publ) has published its Annual Report for 2021

22/04/2022

HarperCollins Presents THE RESILIENT SOCIETY: Economics After Covid by Markus Brunnermeier

22/04/2022

Mind Wars To Organise Mumbai Debate Championship 2021 : Zee Entertainment

ABP Network celebrated Doctors Day with special programming initiatives

Coca-Cola India appointment Devyani Rajya Laxmi Rana as Vice President of Public Affairs for India and Southwest Asia

Coca-Cola India appointment Devyani Rajya Laxmi Rana as Vice President of Public Affairs for India and Southwest Asia

AndTV Actors and Their Favourite Corners at Home!

05/07/2022

Raisins Market to Garner USD 2,315.30 Million Revenue by

05/07/2022

RaphaCure Launches Revolutionary Health Product RaphaNeu for Indian Education Sector

05/07/2022
ADVERTISEMENT
ADVERTISEMENT
Life Care News

Copyright © 2015 - 2021 Lifecarenews.in

LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283

  • Home
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms of Service
  • Editorial Guidelines

Follow Us

No Result
View All Result
  • Home
  • Business
    • BusinessWire
    • GlobeNewswire
    • Banking
  • News
    • Startups
    • Feature News
    • Energy
    • Real Estate
    • Environment
    • Uncategorized
  • Tech
  • Entertainment
    • Lifestyle
    • Fashion
    • Travel
  • Health
    • Food
  • Education
    • Books
  • Technology
  • Automobile
  • Sports
    • Olympic

Copyright © 2015 - 2021 Lifecarenews.in

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Go to mobile version